D
Daniel D. Mikol
Researcher at Amgen
Publications - 74
Citations - 4328
Daniel D. Mikol is an academic researcher from Amgen. The author has contributed to research in topics: Migraine & Placebo. The author has an hindex of 26, co-authored 68 publications receiving 3134 citations. Previous affiliations of Daniel D. Mikol include Thomas Jefferson University & Albert Einstein College of Medicine.
Papers
More filters
Journal ArticleDOI
A Controlled Trial of Erenumab for Episodic Migraine.
Peter J. Goadsby,Uwe Reuter,Yngve Hallström,Gregor Broessner,Jo H. Bonner,Feng Zhang,Sandhya Sapra,Hernan Picard,Daniel D. Mikol,Robert A. Lenz +9 more
TL;DR: Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine–specific medication over a period of 6 months.
Journal ArticleDOI
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart J. Tepper,Messoud Ashina,Uwe Reuter,Jan Lewis Brandes,David Doležil,Stephen D. Silberstein,Paul Winner,Dean Leonardi,Daniel D. Mikol,Robert A. Lenz +9 more
TL;DR: In patients with chronic migraine, erenumab 70 mg and 140 mg reduced the number of monthly migraine days with a safety profile similar to placebo, providing evidence that erenUMab could be a potential therapy for migraine prevention.
Journal ArticleDOI
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol,Frederik Barkhof,P Chang,Patricia K. Coyle,Douglas Jeffery,Steven R. Schwid,B Stubinski,Bernard M. J. Uitdehaag +7 more
TL;DR: There was no significant difference between interferon beta-1a and glatiramer acetate in the primary outcome, and the ability to predict clinical superiority on the basis of results from previous studies might be limited by a trial population with low disease activity.
Journal ArticleDOI
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine:
David W. Dodick,Messoud Ashina,Jan Lewis Brandes,David Kudrow,Michel Lanteri-Minet,V. V. Osipova,Kerry Palmer,Hernan Picard,Daniel D. Mikol,Robert A. Lenz +9 more
TL;DR: As a preventive treatment of episodic migraine, erenumab at a dosage of 70 mg monthly significantly reduced migraine frequency and acute migraine-specific medication use.
Journal ArticleDOI
Oligodendrocyte-myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth.
Vicky Kottis,Pierre Thibault,Daniel D. Mikol,Zhi-Cheng Xiao,Rulin Zhang,Rulin Zhang,Pauline Dergham,Peter E. Braun +7 more
TL;DR: Oligodendrocyte‐myelin glycoprotein is a potent inhibitor of neurite outgrowth from rat cerebellar granule and hippocampal cells; from dorsal root ganglion explants in which growth cone collapse was observed; from rat retinal ganglions neurons; and from NG108 and PC12 cells.